BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC

After going back to the negotiating table, BioNTech and Regeneron have come away with an expanded collaboration pushing their efforts into lung cancer.

The two built upon a previous deal in which researchers evaluated the PD-1 antibody Libtayo in combination with an experimental mRNA cancer vaccine. Whereas the earlier deal centered around a melanoma program, Tuesday’s partnership will focus on a candidate for NSCLC. No financials were disclosed, but the two noted they will share development costs 50-50.